Cardiac CT Function Software Application vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Cardiac CT Function Software Application

by Circle Cardiovascular Imaging

EchoNext

by Pathway Labs

AI Verdict

These tools are adjacent in their focus on cardiac health but differ significantly in their input data and diagnostic approach. Tool A, Cardiac CT Function Software Application, analyzes CT angiography images for detailed structural and functional assessment, ideal for advanced cardiac imaging departments. Tool B, EchoNext, utilizes standard ECGs to screen for hidden structural heart disease, making it suitable for broader, earlier-stage detection in various clinical settings.

Choose Cardiac CT Function Software Application if…

Choose the Cardiac CT Function Software Application if your institution requires in-depth, AI-powered analysis of cardiovascular CT angiography images for precise quantification of cardiac function and detailed structural assessment. This tool is ideal for cardiology and cardiothoracic surgery departments needing comprehensive metrics like ejection fraction, volumes, and even coronary plaque analysis for complex case management and research.

View Cardiac CT Function Software Application →

Choose EchoNext if…

Choose EchoNext if your practice or hospital aims to leverage standard ECGs for early, non-invasive detection of hidden structural heart disease across a broad patient population. This tool is particularly well-suited for primary care, internal medicine, and hospital medicine settings looking to screen for conditions like heart failure, valve disease, and pulmonary hypertension using readily available diagnostic data.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Cardiac CT Function Software Application	EchoNext
Pricing	Contact for pricing	Starts at $600/month
Deployment	On-premise software, integrated into hospital or private practice environments. Server pulls DICOM data from PACS.	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Cardiac CT Function Software Application

Tool A (Cardiac CT Function Software Application) emphasizes a 'seamless user experience' and 'intuitive post-processing analysis' with 'user-friendly tools for manual editing' and 'integrated reporting with infographics and screenshots'. This suggests a strong focus on workflow integration and ease of use for clinicians. While Tool B (EchoNext) is integrated into the OpenEvidence platform, its direct usability features are not as extensively detailed in the provided information.

Clinical Value

EchoNext

Tool B (EchoNext) has demonstrated superior diagnostic accuracy in detecting structural heart disease from ECGs compared to cardiologists, even when cardiologists were assisted by AI. It has also been credited with flagging previously undiagnosed heart failure that led to a heart transplant, showcasing its potential for significant clinical impact and early detection of critical conditions. Tool A provides quantitative metrics for cardiac function, which is valuable, but the comparative diagnostic accuracy and real-world impact of EchoNext are more compelling.

Pricing & Value

EchoNext

Tool B (EchoNext) offers transparent tiered pricing starting at $600/month, with details on different plans and discounts. This allows potential users to understand the cost structure upfront. Tool A (Cardiac CT Function Software Application) requires contacting the vendor for pricing, which makes it less transparent for initial evaluation, although it mentions a flexible subscription model and pay-per-process options.

Enterprise Readiness

Cardiac CT Function Software Application

Tool A (Cardiac CT Function Software Application) is deployed on-premise, integrates with PACS, supports various operating systems and scanner types, and is designed for both community hospitals and enterprise sites. It also highlights 'workflow continuity and reduced burnout' and 'financial sustainability and reimbursement' with a new CPT code for AI-enabled quantitative plaque analysis. Tool B (EchoNext) is available through the OpenEvidence platform and targets broad access, but the details on enterprise-level deployment, integration flexibility, and specific financial benefits are less comprehensive than for Tool A.

Innovation

EchoNext

Tool B (EchoNext) is described as the 'world's first FDA-approved AI detection tool that analyzes electrocardiograms (ECGs) to detect high-risk structural heart disease.' This represents a novel application of AI to a widely available and inexpensive diagnostic test (ECG) for early screening of complex heart conditions that were previously difficult to detect this way. While Tool A utilizes AI/ML for cardiac CT analysis, which is advanced, EchoNext's approach to leveraging ECG data for structural heart disease detection is a more significant paradigm shift in early detection.

Support & Docs

Cardiac CT Function Software Application

Tool A (Cardiac CT Function Software Application) explicitly mentions 'Unmatched User Experience & Support You Can Count On' and 'great customer service' in testimonials. It also lists 'Technical Support' and 'cvi42 Documentation' as resources. Tool B (EchoNext) does not provide specific details regarding its support and documentation offerings in the provided information.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Cardiac CT Function Software Application	EchoNext
Name	Cardiac CT Function Software Application	EchoNext
Company	Circle Cardiovascular Imaging	Pathway Labs
Description	Circle Cardiovascular Imaging's Cardiac CT Function Software Application uses AI/ML to analyze multi-phase, multi-slice cardiovascular CT angiography images, segmenting cardiac structures and quantifying key function metrics like ejection fraction and volumes. It is part of the cvi42 platform, enhancing diagnostic workflows and patient care.	EchoNext is an FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Key Analysis Method	AI/ML to analyze multi-phase, multi-slice cardiovascular CT angiography images	AI-powered ECG analysis
Primary Output	Quantification of cardiac function metrics (EDV, ESV, SV, EF, CO, CI, LV myocardial mass)	Detection of hidden structural heart disease (heart failure, valve disease, pulmonary hypertension)

Videos

Demos, reviews, and walkthroughs featuring Cardiac CT Function Software Application and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows and EHR systems?

Tool A, Circle CVI's cvi42 platform, is designed for workflow optimization, integrating directly into existing PACS and reporting systems like PowerScribe One without requiring expensive HL7 interfaces. This allows for high-throughput analysis and aims to reduce the time from 'scan to report'. Tool B, EchoNext, is available through the OpenEvidence clinical decision support platform, which is used by a large number of U.S. physicians, aiming to integrate the AI screening output into existing physician workflows at the point of care.

What is the accuracy and sensitivity of each tool in detecting cardiac conditions?

Tool A, Circle CVI's Cardiac CT Function Software, uses AI/ML for cardiac structure segmentation and quantification of function metrics, aiming for faster, more reproducible, and accurate interpretations. Tool B, EchoNext, demonstrated higher accuracy (77%) in detecting structural heart problems from ECGs alone compared to cardiologists (64%) in a 2025 study. It achieved an AUROC of 85.2% in internal tests and 78-80% in external validation.

What is the learning curve for physicians to effectively use each tool?

Tool A, cvi42, is described as having intuitive post-processing analysis and a focus on a seamless user experience, suggesting a manageable learning curve for physicians experienced in cardiovascular imaging. Tool B, EchoNext, analyzes standard ECGs, which are routine tests, and its integration into the OpenEvidence platform aims to make it accessible within familiar physician tools, potentially reducing the learning curve for its interpretation.

What kind of customer support can be expected for each tool?

Circle Cardiovascular Imaging (Tool A) emphasizes its commitment to customer service, with a global team offering support in multiple languages and time zones. They report a high customer satisfaction score (CSAT of 4.9 with a 98% satisfaction rate in 2023) and a Net Promoter Score (NPS) of 69, indicating a strong likelihood of customers recommending the product. Information regarding specific customer support for EchoNext (Tool B) is not detailed in the provided facts, beyond its availability through the OpenEvidence platform.

What are the key clinical differences and ideal use cases for each tool?

Tool A, Circle CVI's Cardiac CT Function Software, is designed for detailed analysis of multi-phase, multi-slice cardiovascular CT angiography images, segmenting cardiac structures and quantifying function metrics like ejection fraction and volumes. It's part of a unified platform for cardiac, vascular, and structural heart analysis, suitable for cardiologists, cardiothoracic surgeons, and radiologists. Tool B, EchoNext, analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, acting as a screening tool to identify patients who should proceed to an echocardiogram. It is designed for broad access across specialties like cardiology, family medicine, hospital medicine, and internal medicine.

Are there audit-trail features available in either tool to track AI analysis and physician interaction?

The provided information for both Tool A (Circle Cardiovascular Imaging's Cardiac CT Function Software) and Tool B (EchoNext) does not explicitly detail specific audit-trail features to track AI analysis and physician interaction.